“…Therefore, NFB is a central target for a variety of anti-inflammatory and anti-tumoral drugs (Karin et al, 2004;Karin and Greten, 2005;Aggarwal et al, 2006a;Aggarwal and Shishodia, 2006;Surh, 2003). This paper reports the screening of 24 selected medicinal plants (Table 1), previously mentioned in medicinal folklore or described in herbal text books and literature (Ali-Shtayeh et al, 2000;Atta and Alkofahi, 1998;Balan et al, 2007;Chithra and Leelamma, 2000;Choi and Hwang, 2004;Conforti et al, 2006;Corsi et al, 2002;Giner-Larza et al, 2001;Hernandez et al, 2001;Hibasami et al, 2003;Huang et al, 1994;Inoue et al, 2006;Kaur et al, 2003;Kumar et al, 2004;Manosroi et al, 2006;Matsuda et al, 2000;Ojewole, 2006;Sayyah et al, 2003;Winters, 2006), for their cytotoxicity against mouse fibrosarcoma (L929sA), human benign (MCF7) and metastatic (MDA-MB231) breast cancer cell types using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Furthermore, as anti-inflammatory or anti-tumoral activities of various plant-derived agents, such as genistein, resveratrol, and curcumin have been reported to act through the inhibition of NFB activation (Aggarwal et al, 2006b;Bremner and Heinrich, 2002;Shukla and Gupta, 2004;Vanden Berghe et al, 2006), we further describe the NFB-modulatory activities of 9 out of 24 selected plant extracts, using an NFB reporter gene-based cell assay.…”